Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RF9T
|
|||
| Former ID |
DIB001785
|
|||
| Drug Name |
Lexacalcitol
|
|||
| Synonyms |
KH-106; KH-1060; MC-1357; Vitamin D3 agonist, Leo
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 2 | [1], [2] | |
| Company |
LEO Pharma A/S
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H48O4
|
|||
| Canonical SMILES |
CCC(CC)(CCCOC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O
|
|||
| InChI |
1S/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1
|
|||
| InChIKey |
KLZOTDOJMRMLDX-YBBVPDDNSA-N
|
|||
| CAS Number |
CAS 131875-08-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
822635, 7888546, 11041457, 12014546, 14715307, 14784667, 39321024, 50064338, 50264345, 53787932, 57359236, 103347297, 113872531, 126616813, 126665070, 135025894, 135650456, 138439461, 139426841, 184526821, 184812193, 198951177, 223657688, 223860400, 226395233, 251916472, 251917820, 252225015, 252479370
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vitamin D3 receptor (VDR) | Target Info | Agonist | [3] |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | |||
| Mineral absorption | ||||
| Tuberculosis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Vitamin D metabolism and pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Direct p53 effectors | ||||
| RXR and RAR heterodimerization with other nuclear receptor | ||||
| Retinoic acid receptors-mediated signaling | ||||
| Validated transcriptional targets of deltaNp63 isoforms | ||||
| Validated transcriptional targets of TAp63 isoforms | ||||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Ovarian Infertility Genes | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Vitamin D Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| Nuclear Receptors | ||||
| Vitamin D Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2775). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002985) | |||
| REF 3 | The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology. 1997 Dec;138(12):5485-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.